Találati lista | Tudóstér

1.

001-es BibID:	BIBFORM015794
Első szerző:	Arnson, Yoav
Cím:	Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis a retrospective cohort study and review of the literature / Yoav Arnson, Howard Amital, Nancy Agmon-Levin, Danny Alon, María Sánchez-Castanón, Marcos López-Hoyos, Marco Matucci-Cerinic, Gabriella Szücs, Yinon Shapira, Zoltan Szekanecz, Yehuda Shoenfeld
Dátum:	2011
ISSN:	1568-9972
Megjegyzések:	Low vitamin D serum concentrations have been reported in several autoimmune conditions. The study's aim was to explore such a relationship in a large multinational population of patients with systemic sclerosis (SSc) and to pursue possible clinical and laboratory correlates with vitamin D concentrations. 327 sera samples of European patients with SSc and 141 samples of compatible healthy controls were studied for vitamin D concentrations using the commercial kit LIAISON 25-OH vitamin D assay (Diasorin). Additionally, clinical parameters including the Rodnan skin score, diffusing lung capacity for carbon monoxide (DLCO), systolic pulmonary artery pressure (sPAP), forced vital capacity (FVC), and nailfold video capillaroscopic, erythrocyte sedimentation rate (ESR), anti-nuclear antibodies (ANA and scl70), rheumatoid factor (RF) were investigated. Vitamin D serum concentration was 13.5+/-9.0ng/ml (mean+/-standard deviation) in patients with SSc compared to 21.6+/-9.7ng/ml in a control group (p<0.001). A negative correlation between patients' age and vitamin D concentration (r=-0.2, p<0.05, n=96) was observed. An inverse relationship was found between skin involvement and vitamin D serum concentrations; Patients with a Rodnan skin score of 10 or lower (n=11) had a mean vitamin D concentration of 17.7+/-10.4ng/ml compared to patients with a score above 10 (n=28) 8+/-10.1ng/ml (p=0.02, by the Mann-Whitney test). In conclusion, Patients with SSc have significantly lower serum vitamin D concentrations compared to healthy controls; moreover fibrosis of the cutaneous tissue is inversely related to the vitamin D concentration.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 10 : 8 (2011), p. 490-494. -
További szerzők:	Amital, Howard Agmon-Levin, Nancy Alon, Danny Sánchez-Castanón, María Lopez-Hoyos, Marcos Matucci-Cerinic, Marco Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Shapira, Yinon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:	DOI elektronikus változat Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

2.

001-es BibID:	BIBFORM057885
Első szerző:	Bodoki Levente (PhD hallgató)
Cím:	Four dermatomyositis-specific autoantibodies-anti-TIF1[gamma], anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort / Levente Bodoki, Melinda Nagy-Vincze, Zoltán Griger, Zoe Betteridge, Lászlóné Szöllősi, Katalin Dankó
Dátum:	2014
ISSN:	1568-9972
Megjegyzések:	Idiopathic inflammatory myopathies (IIMs) are chronic systemic autoimmune diseases characterised by symmetrical, proximal muscle weakness. Dermatomyositis represents one subset of IIMs, in which skin rashes are present in addition to muscle weakness. Myositis-specific antibodies can only be detected in myositis, and they are directed against specific proteins found in the cytoplasm or in the nucleus of cells. With this case-based article, we introduce the recently detected anti-TIF1?, anti-NXP2, anti-SAE and anti-MDA5 antibodies that form various clinical groups. These antibodies could be detected in patients with dermatomyositis. The myositis-specific autoantibodies of three hundred and thirty-seven Hungarian patients with IIM were detected. Retrospective analysis of the clinical findings has also been introduced by revision of the medical history. We had twelve patients with anti-TIF1? positivity, four patients with anti-NXP2 positivity and four patients with anti-SAE positivity. We did not have any positive anti-MDA5 patients. The most relevant clinical findings were similar to those seen in previously published reports. Eleven of the twelve patients with anti-TIF1? positivity had classical dermatomyositis. Three of the twelve anti-TIF1? patients had cancer during the disease progression. This was two out of four for the anti-NXP2 subgroup and one in four for the anti-SAE subgroup. In two juvenile dermatomyositis cases, typical ulceration was seen in patients with anti-TIF1? positivity. The frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1?, anti-NXP2 and anti-SAE, respectively. Other extra-muscular manifestations, such as arthralgia, dysphagia, dysphonia and dyspnoea, were also detectable. The myositis subgroups determined by these myositis-specific autoantibodies differ from each other in their symptoms, prognosis and therapy responsiveness. Their detection is helpful for the preparation of an adequate treatment, but in daily diagnostic methods, these antibodies cannot be detected. By presenting our anti-TIF1?, anti-NXP2 and anti-SAE cases, we would like to highlight the clinical role of these antibodies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 13 : 12 (2014), p. 1211-1219. -
További szerzők:	Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Betteridge, Zoe Szőllősi Lászlóné Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

3.

001-es BibID:	BIBFORM114387
035-os BibID:	(Scopus)85169934513
Első szerző:	Caporali, Roberto
Cím:	Start RA Treatment - Biologics or JAK-Inhibitors? / Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Dátum:	2024
ISSN:	1568-9972
Megjegyzések:	Janus Kinase inhibitors (JAKi) have been approved for the treatment of Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatment with efficacy similar to, if not greater than, biologic agents. Recently, concerns over their safety was raised by the results from Oral Surveillance trial suggesting that tofacitinib, one of the JAKi, was associated with higher cardiovascular adverse events and malignancies than TNF inhibitors (TNFi). Since then, regulatory authorities have added warnings to the labels of JAKi. On this purpose, whether rheumatologists should use JAKi as first line advance treatment has become a controversial topic. Some rheumatologists have argued that biologics should be first line advance treatment since there are extensive effectiveness and safety data. In addition, with the advent of biosimilar drugs, they are the most cost-effective treatment. On the other hand, JAKi are very efficacious and are generally safe apart from older and high-risk patients. When TNFi are contraindicated and in certain RA patients, especially when an oral drug is preferable, JAKi have significant advantage providing patients are involved in the decision-making process.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 23 : 1 (2024), p.1-4. _
További szerzők:	Germinario, Sabino Kacsándi Dorottya Choy, Ernest Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat http://dx.doi.org/10.1016/j.autrev.2023.103429
Borító:
Saját polcon:

4.

001-es BibID:	BIBFORM068029
Első szerző:	Chen, Ji-Qing
Cím:	The role of microRNAs in the pathogenesis of autoimmune diseases / Chen Ji-Qing, Papp Gábor, Szodoray Péter, Zeher Margit
Dátum:	2016
ISSN:	1568-9972
Megjegyzések:	MicroRNAs (miRNAs) are single-stranded, endogenous non-coding small RNAs, ranging from 18 to 25 nucleotides in length. Growing evidence suggests that miRNAs are essential in regulating gene expression, cell development, differentiation and function. Autoimmune diseases are a family of chronic systemic inflammatory diseases. Recent findings on miRNA expression profiles have been suggesting their role as biomarkers in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome. In this review, we summarize the characteristics of miRNAs and their functional role in the immune system and autoimmune diseases including systemic lupus erythematosus, primary Sjögren's syndrome, rheumatoid arthritis, systemic sclerosis, multiple sclerosis and psoriasis; moreover, we depict the advantages of miRNAs in modern diagnostics.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk MicroRNAs Multiple sclerosis Primary Sjögren's syndrome Psoriasis Rheumatoid arthritis Systemic lupus erythematosus Systemic sclerosis
Megjelenés:	Autoimmunity Reviews. - 15 : 12 (2016), p. 1171-1180. -
További szerzők:	Papp Gábor (1984-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:	OTKA-101470 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

5.

001-es BibID:	BIBFORM035127
Első szerző:	Doria, Andrea
Cím:	Controversies in rheumatism and autoimmunity / Andrea Doria, Chaim Putterman, Piercarlo Sarzi-Puttini, Zoltán Szekanecz, Yehuda Shoenfeld
Dátum:	2012
ISSN:	1568-9972
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban rheumatism autoimmunity arthritis endothelíal dysfunction biologics külföldön készült közlemény
Megjelenés:	Autoimmunity Reviews. - 11 : 8 (2012), p. 555-557. -
További szerzők:	Putterman, Chaim Sarzi-Puttini, Piercarlo Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

6.

001-es BibID:	BIBFORM067428
Első szerző:	Elshabrawy, Hatem A.
Cím:	TLRs, future potential therapeutic targets for RA / Hatem A. Elshabrawy, Abdul E. Essani, Zoltán Szekanecz, David A. Fox, Shiva Shahrara
Dátum:	2017
ISSN:	1568-9972
Megjegyzések:	Toll like receptors (TLR)s have a central role in regulating innate immunity and in the last decade studies have begun to reveal their significance in potentiating autoimmune diseases such as rheumatoid arthritis (RA). Earlier investigations have highlighted the importance of TLR2 and TLR4 function in RA pathogenesis. In this review, we discuss the newer data that indicate roles for TLR5 and TLR7 in RA and its preclinical models. We evaluate the pathogenicity of TLRs in RA myeloid cells, synovial tissue fibroblasts, T cells, osteoclast progenitor cells and endothelial cells. These observations establish that ligation of TLRs can transform RA myeloid cells into M1 macrophages and that the inflammatory factors secreted from M1 and RA synovial tissue fibroblasts participate in TH-17 cell development. From the investigations conducted in RA preclinical models, we conclude that TLR-mediated inflammation can result in osteoclastic bone erosion by interconnecting the myeloid and TH-17 cell response to joint vascularization. In light of emerging unique aspects of TLR function, we summarize the novel approaches that are being tested to impair TLR activation in RA patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Rheumatoid arthritis (RA) Toll like receptors (TLR)s Inflammation Bone erosion M1 macrophages TH-17 cells
Megjelenés:	Autoimmunity Reviews 16 : 2 (2017), p. 103-113. -
További szerzők:	Essani, Abdul E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Fox, David A. Shahrara, Shiva
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

7.

001-es BibID:	BIBFORM082169
035-os BibID:	(PMID)31733368 (cikkazonosító)102421
Első szerző:	Favalli, Ennio Giulio
Cím:	The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis / Ennio Giulio Favalli, Marco Matucci-Cerinic, Zoltan Szekanecz
Dátum:	2020
ISSN:	1568-9972
Megjegyzések:	Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that, if untreated, can lead to disability and reduce the life expectancy of affected patients. Over the last two decades the improvement of knowledge of the pathogenetic mechanisms leading to the development of the disease has profoundly changed the treatment strategies of RA through the development of biotechnological drugs (bDMARDs) directed towards specific proinflammatory targets involved in the RA network. To date, the therapeutic armamentarium for RA includes ten bDMARDs able to produce the depletion B-cells, the blockade of three different pro-inflammatory cytokines (tumour necrosis factor alpha, interleukin-6 and interleukin-1), or the inhibition of T-cell co-stimulation. The introduction of these new compounds has dramatically improved outcomes in the short and long term, although still a significant proportion of patients are unable to reach or maintain the treatment target over time. The identification of the fundamental role of Janus kinases in the process of transduction of the inflammatory signal within the immune cells has recently provided the opportunity to use the new pharmacological class of small molecules for the therapy of RA, further increasing the number of treatment options. In this review the PROS and CONS of these two drug classes will be discussed, trying to provide the evidence currently available to make the right choice based on the analysis of the efficacy and safety profile of the different drugs on the market and close to marketing.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Biologic agents Efficacy JAK inhibitors Personalised medicine Rheumatoid arthritis Safety profile
Megjelenés:	Autoimmunity Reviews. - 19 : 1 (2020), p. 1-8. -
További szerzők:	Matucci-Cerinic, Marco Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

8.

001-es BibID:	BIBFORM092833
Első szerző:	Frantz, Camelia
Cím:	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database / Camelia Frantz, Dorte Huscher, Jérôme Avouac, Eric Hachulla, Alexandra Balbir-Gurman, Gabriela Riemekasten, Elise Siegert, Maria-Grazia Lazzaroni, Patricia E. Carreira, Serena Vettori, Elisabetta Zanatta, Susanne Ullman, Laszlo Czirjàk, Otylia Kowal-Bielecka, Oliver Distler, Marco Matucci-Cerinic, Yannick Allanore, EUSTAR
Dátum:	2020
ISSN:	1568-9972
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 19 : 2 (2020), p. 1-7. -
További szerzők:	Huscher, Dörte Avouac, Jérôme Hachulla, Eric Balbir Gurman, Alexandra Riemekasten, Gabriela Siegert, Elise Lazzaroni, Maria-Grazia Carreira, Patricia E. Vettori, Serena Zanatta, Elisabetta Ullman, Susanne Czirják László Kowal-Bielecka, Otylia Distler, Oliver Matucci-Cerinic, Marco Allanore, Yannick Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) EUSTAR
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

9.

001-es BibID:	BIBFORM013920
Első szerző:	Hajas Ágota Helga (orvos)
Cím:	Vitamin D insufficiency in a large MCTD population / Hajas Ágota, Sándor János, Csáthy László, Csipő István, Baráth Sándor, Paragh György, Seres Ildikó, Szegedi Gyula, Shoenfeld Yehuda, Bodolay Edit
Dátum:	2011
ISSN:	1568-9972
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 10 : 6 (2011), p. 317-324. -
További szerzők:	Sándor János (1966-) (orvos-epidemiológus) Csáthy László (1979-) (laboratóriumi szakorvos) Csípő István (1953-) (vegyész) Baráth Sándor (1977-) (biológus) Paragh György (1953-) (belgyógyász) Seres Ildikó (1954-) (biokémikus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI elektronikus változat
Borító:
Saját polcon:

10.

001-es BibID:	BIBFORM007068
Első szerző:	Karosi Tamás (fül-orr-gégész)
Cím:	Otosclerosis : an autoimmune disease? / Karosi, T., Szekanecz, Z., Sziklai, I.
Dátum:	2009
ISSN:	1873-0183 (Electronic)
Megjegyzések:	To review our current knowledge of the etiopathogenesis of otosclerotic bone remodeling including genetics, viral infection, autoimmunity and inflammation and to discuss disease pathogenesis with relevance for pharmacotherapy. SYSTEMATIC REVIEW METHODOLOGY: Relevant publications on the etiopathogenesis, molecular biology, genetics and histopathology of otosclerosis from 1984 to 2009 were analyzed. RESULTS AND CONCLUSIONS: Otosclerosis is a bone remodeling disorder of the human otic capsule, however, the etiopathogenesis remains unclear. Genetic predisposition, disturbed bone metabolism, persistent measles virus infection, autoimmunity, hormonal and environmental factors also may play contributing roles in the pathogenesis of otosclerosis. Since, diagnosis of otosclerosis is still based on histopathological examination of the removed stapes footplate, systemic prospective studies based on comprehensive histopathological and molecular biological analysis are necessary to get further information about the background of disease.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 9 : 2 (2009), p. 95-101. -
További szerzők:	Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sziklai István (1954-) (fül-orr-gégész)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon:

11.

001-es BibID:	BIBFORM109481
035-os BibID:	(cikkazonosító)103311 (Scopus)85150926379 (WoS)000951636500001
Első szerző:	Mogyoróssy Sándor
Cím:	Novel aspects of muscle involvement in immune-mediated inflammatory arthropathies and connective tissue diseases / Mogyoróssy Sándor, Nagy-Vincze Melinda, Griger Zoltán, Dankó Katalin, Szabó Nóra Anna, Szekanecz Zoltán, Szűcs Gabriella, Szántó Antónia, Bodoki Levente
Dátum:	2023
ISSN:	1568-9972
Megjegyzések:	Myalgia, myopathy and myositis are the most important types of muscle impairment in immune-mediated inflammatory arthropathies and connective tissue diseases. Multiple pathogenetic and histological changes occur in the striated muscles of these patients. Clinically, the most important muscle involvement is the one that causes complaints to the patients. In everyday practice, insidious symptoms present a serious problem for the clinician; in many cases, it is difficult to decide when and how to treat the muscle symptoms that are often present only subclinically. In this work, authors review the international literature on the types of muscle problems in autoimmune diseases. In scleroderma histopathological picture of muscle shows a very heterogeneous picture, necrosis and atrophy are common. In rheumatoid arthritis and systemic lupus erythematosus, myopathy is a much less defined concept, further studies are needed to describe it. According to our view, overlap myositis should be recognized as a separate entity, preferably with distinct histological and serological characteristics. More studies are needed to describe muscle impairment in autoimmune diseases which may help to explore this topic more in depth and be of clinical use.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Myalgia Myopathy Myositis Rheumatoid arthritis Systemic sclerosis Systemic lupus erythematosus
Megjelenés:	Autoimmunity Reviews. - 22 : 5 (2023), p. 1-7. -
További szerzők:	Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Szabó Nóra Anna (1976-) (orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Antónia (1977-) (belgyógyász, allergológus és klinikai immunológus) Bodoki Levente (1986-) (PhD hallgató)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

12.

001-es BibID:	BIBFORM033045
Első szerző:	Nakken, Britt
Cím:	B-cells and their targeting in rheumatoid arthritis : current concepts and future perspectives / Nakken B., Munthe L. A., Konttinen Y. T., K. Sandberg A., Szekanecz Z., Alex P., Szodoray P.
Dátum:	2011
ISSN:	1568-9972
Megjegyzések:	Rheumatoid arthritis (RA) is a chronic, autoimmune disease that affects primarily the joints and without proper treatment results in their progressive destruction. In addition to T-cells, B-cells play a central role in the pathogenesis of this disease. The synovial tissue is an active site of B-cell accumulation, plasma cell differentiation and in situ antibody-production in RA. As part of the complex role of B-cells in the joints and synovial membrane of RA patients, B cells secrete chemokines and cytokines and may function as antigen presenting cells. The multifaceted pathogenic function of B-cells identifies them as excellent targets for immunosuppressive therapy. B-cell targeting involves a wide spectrum of molecules, for example the B-cell antigen CD20 that allows specific and effective B-cell depletion. Another target, CD79, expressed by B-cell and plasma cell precursors is an obvious candidate that induces apoptosis as well as inhibition of B-cell receptor (BCR) activation and possibly depletion of ectopic germinal centers (GC). Inhibition of B-cell co-stimulatory molecules such as CD40, CD80/86 and ICOS, can lead to diminished B-cell activation. Moreover, anti-chemokine and anti-cytokine therapies can be efficacious in RA by the disruption of B-cell activation and autoantibody production. B-cell synovial migration and ectopic GC formation. Finally, targeting the signal transduction pathways required for proximal BCR signaling has also been found efficacious in early clinical trials in RA. Even so, some B cells inhibit immune responses, these regulatory B cells may play a part in immune regulation in patients and it is unclear what effects B cell depletion strategies have in terms of such B cell subsets. This review discusses current strategies of targeting B-cells as therapeutic candidates in the management of RA. Better insights into the pathogenic role of B-cells provide efficacious opportunities to improve both therapy and prognosis of patients with RA.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 11 : 1 (2011), p. 28-34. -
További szerzők:	Munthe, Ludvig A. Konttinen, Yrjö T. Klokk Sandberg, Anna Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Alex, Philip Szodoray Péter (1973-) (belgyógyász, orvos)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

Rekordok letöltése

1 2 3

Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.